https://www.selleckchem.com/pr....oducts/rilematovir.h
NLR was higher in NMOSD patients during the first attack compared with HC (2.9 ± 1.6 vs 1.8 ± 0.6; p0.0001). Regardless of immunosuppressant's initiation at disease onset, NLR remained higher in NMOSD patients at 12 (2.8 ± 1.3; p0.0001) and 24 (3.1 ± 1.6; p0.0001) months. No association was found at 12 and 24 months between the log-transformed NLR and the presence of relapses, new/enlarging and/or contrast-enhancing MRI lesions, and/or physical disability. In this cohort of LATAM patients with AQP4-IgG-positive NMOSD, NL
Like
Comment
Share
